These findings underscore a potential relevance of B-cell intrinsic RANK in human myeloma and clarify the previously suggested anti-myeloma effects of denosumab, which targets RANKL in the treatment of bone disease [42]. The gene discussed is TNFRSF11A; the disease is plasma cell myeloma.